This was attributed to the augmented level of cytotoxic infiltration into tumor lesions, highlighting the potential of KRAS peptide vaccines in advancing available prophylactic treatments for pancreatic cancer. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.